1. Pink Sheet
  2. >>Market Access
  4. >>Medicare

Aduhelm Medicare Coverage: House Republicans Push For CMS To Collaborate With US FDA

 
• By Brenda Sandburg

More than 70 Republican representatives object to CMS draft national coverage determination for Alzheimer’s disease drugs. They ask if CMS will treat future drugs approved under the accelerated approval pathway differently and how it will coordinate with FDA.

Alzheimer's collaboration
Republicans want CMS to work with FDA on Alzheimer's drug coverage decision • Source: Alamy

Republican members of the House joined forces to try to get the Centers for Medicare and Medicaid Services to drop its proposal to restrict Medicare coverage for Alzheimer’s disease drugs, advocating that the agency work with the US Food and Drug Administration in making its decision.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Medicare

Stand-Alone PDP Market Lives to Fight Another Day, Enrollment Data Shows

 
• By Leslie Small

No mass exodus was seen from stand-alone prescription drug plans to Medicare Advantage drug plans between 2024 and 2025, according to one actuary.

Proposed HHS Budget Would Eliminate Medicare Negotiation Program Start-Up Funding

 
• By Cathy Kelly

The preliminary budget document supports legislation clawing back funds appropriated for the program.

Medicare Price Negotiation: Trump Order Adds Momentum To ‘Pill Penalty’ Fix

 
• By Cathy Kelly

Wide-ranging executive order to lower drug prices also hints at changes in upcoming guidance on the Medicare price negotiation program but few other potentially impactful near-term actions.

GLP-1 Drug Coverage Growing For Obesity In Medicaid, But Only For Diabetes In Medicare

 
• By Cathy Kelly

Coverage data from the two programs suggest Medicare beneficiaries may be more disappointed than Medicaid enrollees by the Trump Administration’s decision not to mandate the programs cover obesity drugs.

More from Government Payers